Track record · closed signal

UnitedHealth Group Incorporated (UNH) — closed signal from December 21, 2025

Partial Published before the outcome was known, scored automatically when the window closed on March 21, 2026.

Predicted vs. what happened

UNH price · publication thesis → realized outcomesplit-adjusted
$327.42 Published $366.71 Target $275.59 Window close $357.87 Peak
$320.00 – $332.00Entry zone — fair-value band
$327.42Published — price the day we called it
$366.71Target — the price the thesis aimed for
$357.87Peak — highest point inside the window, not a realized return
$275.59Window close — end-of-window price, context only

What happened

Partial

Reached 78% of the predicted growth at its peak, without hitting the target.

Peak price
$357.87
peak on January 23, 2026 — not a realized return
Peak gain
+9.3%
peak, from the publication price
Window close
$275.59
end-of-window price, context only
Days to target
Window
December 21, 2025 – March 21, 2026

The thesis — published December 21, 2025

Predicted growth
+12%
over the measurement window
Target price
$366.71
the price the thesis aimed for
Entry zone
$320.00 – $332.00
the fair-value band we waited for
Price at publication
$327.42
published December 21, 2025
Confidence
60%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

UnitedHealth looks like a contrarian rebound: shares have fallen a lot and some signs show buying interest returning. The company announced 23 corrective actions and Optum Rx changed its reimbursement approach to try to improve profits into 2026. These steps increase the chance of stabilization, but audit and headline risk could still cause sharp drops. Treat this as a short-term bounce over the next 0-3 months.

Primary drivers

  • Company plans and payer changes aim to fix profit margins
  • Shares are far down, so a quick rebound is possible
  • Healthcare firms tend to hold up when markets wobble
  • Public audits and headlines could still push shares lower

How it played out

UNH: rebound fell short of the target

Lyra published UNH on 2025-12-21 at $327.42 as a short-term contrarian rebound. The thesis expected 12% growth to $366.71. It pointed to company plans, payer changes, a possible quick rebound after a large fall, healthcare defensiveness, and audit and headline risk that could still push shares lower.

Inside the window, UNH rose to a peak of $357.87 on 2026-01-23, a 9.3% gain. That stayed below the $366.71 target. It never got there. By 2026-03-21, the stock ended at $275.59. The thesis partly played out early, then missed the target and finished below the publication price.

What happened during the window

On 2026-01-27, UnitedHealth reported fourth-quarter revenue of $113.2 billion and gave 2026 revenue guidance of greater than $439 billion. MarketWatch reported that the stock fell after that update.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.